Skip to main content
ADXN
NASDAQ Life Sciences

Addex Therapeutics Reports Critical Going Concern Warning, Low Cash, and Material Internal Control Weakness in Annual Report

Analysis by Arik Shkolnikov
Sentiment info
Negative
Importance info
9
Price
$6.81
Mkt Cap
$7.221M
52W Low
$5.41
52W High
$12.05
Market data snapshot near publication time

summarizeSummary

Addex Therapeutics' annual report reveals a substantial doubt about its ability to continue as a going concern beyond mid-June 2026, driven by a significant net loss and critically low cash reserves, compounded by a material weakness in internal financial controls.


check_boxKey Events

  • Going Concern Warning Issued

    Independent auditors issued a going concern warning, stating that existing cash and cash equivalents are only sufficient to fund operations through mid-June 2026, raising substantial doubt about the company's future viability.

  • Significant Net Loss and Critically Low Cash

    The company reported a net loss of CHF 6.7 million for the fiscal year 2025 and a critically low cash balance of CHF 1.6 million as of December 31, 2025.

  • Material Weakness in Internal Controls

    Management concluded that internal control over financial reporting was not effective as of December 31, 2025, due to a material weakness identified during the preparation of financial statements.

  • Major Partnership Terminated

    Janssen Pharmaceuticals terminated the ADX71149 development program and returned all related intellectual property to Addex on April 17, 2025.


auto_awesomeAnalysis

This annual report presents a dire financial outlook for Addex Therapeutics. The explicit "going concern" warning from the independent auditor, coupled with a very limited cash runway of just over a month, indicates an urgent need for significant capital. The substantial net loss for the year further highlights the company's cash burn. The termination of the Janssen partnership for ADX71149 removes a key development program and potential future revenue stream. Furthermore, the disclosure of a material weakness in internal financial controls is a serious governance issue that can erode investor confidence and complicate future financing efforts. While the company has initiated a new collaboration and restarted an ATM program, these are unlikely to fully offset the immediate and severe financial challenges.

At the time of this filing, ADXN was trading at $6.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.2M. The 52-week trading range was $5.41 to $12.05. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed ADXN - Latest Insights

ADXN
May 15, 2026, 4:00 PM EDT
Filing Type: 20-F
Importance Score:
9
ADXN
Apr 30, 2026, 6:05 AM EDT
Filing Type: 6-K
Importance Score:
8
ADXN
Apr 30, 2026, 1:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
ADXN
Apr 29, 2026, 6:05 AM EDT
Filing Type: 6-K
Importance Score:
7
ADXN
Apr 29, 2026, 1:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
ADXN
Apr 21, 2026, 1:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
ADXN
Feb 03, 2026, 6:05 AM EST
Filing Type: 6-K
Importance Score:
7
ADXN
Jan 07, 2026, 6:05 AM EST
Filing Type: 6-K
Importance Score:
7